10 IPOs brought in $1.3 billion this past week, along with 3 SPACs raising $540 million. With a flood of biotechs, most of the IPOs this week had heavy insider buying, and no revenue. They traded very well, however, averaging a 27% gain. The week's worst IPO...read more
Xeris Pharmaceuticals, which is developing a novel formulation of an injectable hypoglycemia treatment, raised $86 million by offering 5.7 million shares at $15, the midpoint of the $14 to $16 range. It had previously filed to offer 5.0 million shares. Xeris...read more
Helped by a strong market, the steady stream of June IPOs should continue in the week ahead with eleven companies scheduled to raise a combined $1.4 billion. SMB payments processor i3 Verticals and triple net lease REIT ...read more
Xeris Pharmaceuticals, which is developing a novel formulation of an injectable hypoglycemia treatment, announced terms for its IPO on Monday. The Chicago, IL-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to...read more
US IPO Weekly Recap: Biotechs boom in a 13-deal torrent
10 IPOs brought in $1.3 billion this past week, along with 3 SPACs raising $540 million. With a flood of biotechs, most of the IPOs this week had heavy insider buying, and no revenue. They traded very well, however, averaging a 27% gain. The week's worst IPO...read more
Xeris Pharmaceuticals prices upsized $86 million IPO at $15 midpoint
Xeris Pharmaceuticals, which is developing a novel formulation of an injectable hypoglycemia treatment, raised $86 million by offering 5.7 million shares at $15, the midpoint of the $14 to $16 range. It had previously filed to offer 5.0 million shares. Xeris...read more
US IPO Week Ahead: Health care deals lead 11-IPO week
Helped by a strong market, the steady stream of June IPOs should continue in the week ahead with eleven companies scheduled to raise a combined $1.4 billion. SMB payments processor i3 Verticals and triple net lease REIT ...read more
Glucagon pen developer Xeris Pharmaceuticals sets terms for $75 million IPO
Xeris Pharmaceuticals, which is developing a novel formulation of an injectable hypoglycemia treatment, announced terms for its IPO on Monday. The Chicago, IL-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to...read more